Fresenius Medical Care and Access Industries-backed Humacyte will merge with Alpha Healthcare Acquisition Corp to become a public business with a market cap of $1.1bn.

Merck and Novartis joined a host of philanthropic and state-backed entities for a $300m fund that will invest in medical technologies for conditions often ignored by venture capital.

Rogue has achieved a first close for its fourth fund, although it is as-yet unclear whether Oregon State University is again an investor.

The Medtronic-backed medical device maker has pulled in $108m in equity financing just under a year after delisting.

University of Oxford and OSI have both returned for a $95.4m series C round that also included GV and, through the conversion of a note, Eli Lilly.

GV has returned for a $95.4m series C round that also included Eli Lilly through the conversion of a $10m note secured as part of a collaboration agreement last year.

The Legend Holdings-backed digital medical platform has raised fresh capital for a series A round led by Qiming Venture Partners.

Amadeus Capital Partners has bought a stake in the Amgen and Illumina-backed company through a secondary transaction, valuing it at around $2.4bn.

Cambrian Biopharma has backed a round that will go toward further developing Vita’s lead candidate, VTA-110, for muscular dystrophy treatments.

Amadeus Capital Partners has bought a stake in the University of Oxford spinout through a secondary transaction, valuing it at around $2.4bn.